PH12014501258A1 - Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof - Google Patents
Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereofInfo
- Publication number
- PH12014501258A1 PH12014501258A1 PH12014501258A PH12014501258A PH12014501258A1 PH 12014501258 A1 PH12014501258 A1 PH 12014501258A1 PH 12014501258 A PH12014501258 A PH 12014501258A PH 12014501258 A PH12014501258 A PH 12014501258A PH 12014501258 A1 PH12014501258 A1 PH 12014501258A1
- Authority
- PH
- Philippines
- Prior art keywords
- therapeutic use
- preparation process
- process therefor
- pyrazolopyridine derivatives
- derivatives
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 150000005229 pyrazolopyridines Chemical class 0.000 title 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1161589A FR2984325A1 (fr) | 2011-12-14 | 2011-12-14 | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| PCT/EP2012/075328 WO2013087744A1 (en) | 2011-12-14 | 2012-12-13 | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014501258A1 true PH12014501258A1 (en) | 2014-09-08 |
Family
ID=47458918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014501258A PH12014501258A1 (en) | 2011-12-14 | 2014-06-04 | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20140350006A1 (https=) |
| EP (1) | EP2791137B1 (https=) |
| JP (2) | JP6214551B2 (https=) |
| KR (1) | KR102012058B1 (https=) |
| CN (2) | CN106317056B (https=) |
| AU (1) | AU2012351712B2 (https=) |
| BR (1) | BR112014014452A2 (https=) |
| CA (1) | CA2857749A1 (https=) |
| CL (1) | CL2014001539A1 (https=) |
| CO (1) | CO7000778A2 (https=) |
| DK (1) | DK2791137T3 (https=) |
| EA (1) | EA027421B1 (https=) |
| ES (1) | ES2719444T3 (https=) |
| FR (1) | FR2984325A1 (https=) |
| HK (1) | HK1198442A1 (https=) |
| IL (1) | IL232906A (https=) |
| MA (1) | MA35841B1 (https=) |
| MX (1) | MX358422B (https=) |
| PH (1) | PH12014501258A1 (https=) |
| PL (1) | PL2791137T3 (https=) |
| PT (1) | PT2791137T (https=) |
| SG (2) | SG10201510204QA (https=) |
| WO (1) | WO2013087744A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2984325A1 (fr) * | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| US10138235B2 (en) | 2011-12-14 | 2018-11-27 | Sanofi | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof |
| EA201591324A1 (ru) | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| DK2970265T3 (en) | 2013-03-15 | 2018-10-01 | Plexxikon Inc | HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| EA030558B1 (ru) * | 2013-06-14 | 2018-08-31 | Санофи | Применение производных пиразолопиридина для лечения рака мочевого пузыря |
| KR102344105B1 (ko) | 2014-08-18 | 2021-12-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모노시클릭 피리딘 유도체의 염 및 이의 결정 |
| EP3275442B1 (en) | 2015-03-25 | 2021-07-28 | National Cancer Center | Therapeutic agent for bile duct cancer |
| WO2017053604A1 (en) | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Potent antiviral pyrazolopyridine compounds |
| CN108367000A (zh) | 2015-12-17 | 2018-08-03 | 卫材R&D管理有限公司 | 用于乳腺癌的治疗剂 |
| MX2018016257A (es) | 2016-07-07 | 2019-11-21 | Therachon Sas | Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos. |
| US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| MX2020008265A (es) * | 2018-02-16 | 2020-09-21 | UCB Biopharma SRL | Derivados farmaceuticos del anillo heterobiciclico 6,5. |
| US11219619B2 (en) | 2018-03-28 | 2022-01-11 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
| CN108774224B (zh) * | 2018-04-23 | 2020-10-30 | 浙江大学 | 吡唑并[3,4-b]吡啶类化合物及其制备方法和应用 |
| CN110833556A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗肝纤维化的用途 |
| WO2020178316A1 (en) * | 2019-03-05 | 2020-09-10 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. | 5- or 7-azaindazoles as beta-lactamase inhibitors |
| CN118791483B (zh) * | 2024-07-01 | 2025-10-21 | 郑州大学 | 一种1H-吡唑并[3,4-b]吡啶类衍生物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| DE102004061288A1 (de) * | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
| RU2387653C2 (ru) * | 2005-05-16 | 2010-04-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназ |
| WO2006130673A1 (en) * | 2005-05-31 | 2006-12-07 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| FR2889526B1 (fr) * | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| KR101104666B1 (ko) * | 2006-09-06 | 2012-01-13 | 에프. 호프만-라 로슈 아게 | 단백질 키나제 억제제로서의 헤테로아릴 유도체 |
| KR20090031122A (ko) * | 2007-09-21 | 2009-03-25 | 주식회사 중외제약 | 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물 |
| JP4686650B2 (ja) * | 2007-11-30 | 2011-05-25 | ファイザー・リミテッド | 新規なグルココルチコイド受容体アゴニスト |
| TW201035098A (en) * | 2008-12-30 | 2010-10-01 | Arqule Inc | Substituted imidazolyl-5,6-dihydrobenzo[n] isoquinoline compounds |
| FR2951172B1 (fr) * | 2009-10-13 | 2014-09-26 | Pf Medicament | Derives pyrazolopyridines en tant qu'agent anticancereux |
| LT3001903T (lt) * | 2009-12-21 | 2018-01-10 | Samumed, Llc | 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas |
| WO2012019954A1 (en) * | 2010-08-12 | 2012-02-16 | Evotec (Uk) Ltd. | Pyrazolopyridine compounds as pde10a inhibitors |
| FR2984325A1 (fr) * | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
-
2011
- 2011-12-14 FR FR1161589A patent/FR2984325A1/fr active Pending
-
2012
- 2012-12-13 WO PCT/EP2012/075328 patent/WO2013087744A1/en not_active Ceased
- 2012-12-13 JP JP2014546500A patent/JP6214551B2/ja active Active
- 2012-12-13 CN CN201610708994.1A patent/CN106317056B/zh active Active
- 2012-12-13 AU AU2012351712A patent/AU2012351712B2/en not_active Ceased
- 2012-12-13 MX MX2014007168A patent/MX358422B/es active IP Right Grant
- 2012-12-13 CA CA2857749A patent/CA2857749A1/en not_active Abandoned
- 2012-12-13 ES ES12808328T patent/ES2719444T3/es active Active
- 2012-12-13 US US14/364,420 patent/US20140350006A1/en not_active Abandoned
- 2012-12-13 KR KR1020147019030A patent/KR102012058B1/ko not_active Expired - Fee Related
- 2012-12-13 EP EP12808328.4A patent/EP2791137B1/en active Active
- 2012-12-13 BR BR112014014452A patent/BR112014014452A2/pt not_active Application Discontinuation
- 2012-12-13 DK DK12808328.4T patent/DK2791137T3/en active
- 2012-12-13 CN CN201280069679.9A patent/CN104114555B/zh active Active
- 2012-12-13 PT PT12808328T patent/PT2791137T/pt unknown
- 2012-12-13 PL PL12808328T patent/PL2791137T3/pl unknown
- 2012-12-13 SG SG10201510204QA patent/SG10201510204QA/en unknown
- 2012-12-13 HK HK14111927.9A patent/HK1198442A1/xx unknown
- 2012-12-13 EA EA201491149A patent/EA027421B1/ru not_active IP Right Cessation
- 2012-12-13 SG SG11201402851TA patent/SG11201402851TA/en unknown
-
2014
- 2014-06-01 IL IL232906A patent/IL232906A/en active IP Right Grant
- 2014-06-04 PH PH12014501258A patent/PH12014501258A1/en unknown
- 2014-06-11 CL CL2014001539A patent/CL2014001539A1/es unknown
- 2014-07-02 MA MA37174A patent/MA35841B1/fr unknown
- 2014-07-10 CO CO14149160A patent/CO7000778A2/es unknown
-
2017
- 2017-03-07 US US15/451,970 patent/US20170231998A1/en not_active Abandoned
- 2017-07-07 JP JP2017133321A patent/JP2017206544A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501258A1 (en) | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof | |
| MX349004B (es) | Nuevos compuestos. | |
| PH12015502839B1 (en) | Antiviral compounds | |
| PH12013500554A1 (en) | Process for preparing pan-cdk inhibitors of the formula (i) and intermediates in the preparation | |
| AU2012213775A8 (en) | 7-azaindole derivatives | |
| PH12015500376A1 (en) | Novel bicyclic pyridinones | |
| EA033455B1 (ru) | Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе | |
| MD20150048A2 (ro) | Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K | |
| IN2015KN00323A (https=) | ||
| ZA201305582B (en) | Process for the preparation of 4-amino-5-fluoro-3-halo-6-(sunstituted)picolinates | |
| GEP201706690B (en) | Novel process for making compounds for use in treatment of cancer | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| MX2013007567A (es) | Procedimiento para preparar poliestereteroles. | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| MX339460B (es) | Derivados de benzazol como ligandos del receptor h4 de histamina. | |
| GB201107985D0 (en) | Process | |
| MX2014009084A (es) | Derivados de pirimidooxazocina como inhibidores de mtor. | |
| IN2015DN00085A (https=) | ||
| TN2015000095A1 (en) | Macrolide derivatives, preparation thereof and therapeutic use thereof | |
| LT2671871T (lt) | Nauji (aza)benzhidrileterio dariniai, jų gamybos būdai, ir jų panaudojimas kaip h4-receptoriaus ligandų, skirtų terapiniam pritaikymui | |
| IN2014DN07498A (https=) | ||
| MX2013005624A (es) | Nuevos derivados de indolizina, su preparacion y su aplicacion en terapeutica. | |
| TN2013000128A1 (en) | Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation | |
| PL396871A1 (pl) | Kwas naftaleno-1,4-difosfonowy, sposób wytwarzania kwasu naftaleno-1,4-difosfonowego i zastosowanie kwasu naftaleno-1,4-difosfonowego | |
| HUP1100240A2 (en) | Novel coupling process for the preparation of pharmeceutically active ingredient |